Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib with Gemcitabine and Nab-paclitaxel in Locally Advanced PDAC
NCT06361030Phase 2Not yet recruiting
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Surgical conversion rate at 24 weeks. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06361030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361030.